Skip to main content

Table 1 Baseline characteristics of the study population

From: Association of plasma proteomics with incident coronary heart disease in individuals with and without type 2 diabetes: results from the population-based KORA study

Characteristics

Discovery study - KORA S4

Validation study - KORA-Age1

With T2D (n = 228)

Without T2D (n = 1264)

With T2D (n = 165)

Without T2D (n = 723)

CHD cases

(n = 45)

Noncases

(n = 183)

CHD cases

(n = 102)

Noncases

(n = 1162)

CHD cases

(n = 19)

Noncases

(n = 146)

CHD cases

(n = 51)

Noncases

(n = 672)

Age (years)

66 (62, 70)

64 (60, 69)

67 (61, 70)

63 (59, 68)

79 (74, 85)

76 (71, 80)

77 (73, 81)

74 (69, 80)

Male (%)

35 (77.8)

91 (49.7)

68 (66.7)

546 (47.0)

8 (42.1)

73 (50.0)

32 (62.7)

307 (45.7)

Systolic blood pressure (mmHg)

138.5 (130.5, 161.0)

145.0 (132.5, 156.0)

141.0 (128.1, 151.5)

132.5 (120.0, 146.0)

146.0 (132.0, 169.8)

137.8 (124.0, 149.4)

139.5 (126.0, 152.3)

137.0 (124.5, 149.5)

Diastolic blood pressure (mmHg)

80.0 (73.5, 91.0)

82.5 (76.0, 88.5)

80.8 (74.0, 87.5)

79.5 (73.0, 86.5)

75.0 (63.3, 85.8)

73.5 (66.5, 82.0)

73.0 (68.0, 83.3)

76.5 (70.0, 83.0)

Total cholesterol (mmol/l)

5.8 (5.3, 6.6)

6.0 (5.3, 6.8)

6.2 (5.7, 6.9)

6.3 (5.6, 7.0)

4.9 (4.4, 5.3)

5.2 (4.5, 5.9)

5.2 (4.3, 6.3)

5.6 (4.9, 6.3)

HDL-cholesterol (mmol/l)

1.2 (1.0, 1.4)

1.3 (1.1, 1.5)

1.4 (1.1, 1.7)

1.5 (1.3, 1.8)

1.3 (1.1, 1.6)

1.2 (1.1, 1.5)

1.2 (1.0, 1.6)

1.5 (1.2, 1.7)

BMI (kg/m2)

30.6 (28.1, 34.3)

30.2 (27.6, 33.4)

28.4 (26.2, 30.7)

27.6 (25.3, 30.4)

29.4 (25.7, 33.0)

30.6 (27.9, 34.4)

27.3 (25.3, 30.1)

27.6 (25.3, 30.2)

Fasting glucose (mmol/l) a

7.5 (6.5, 8.3)

7.0 (6.2, 7.6)

5.5 (5.1, 5.9)

5.4 (5.1, 5.8)

-

-

-

-

2-hour glucose (mmol/l) b

12.3 (9.8, 14.9)

12.1 (10.4, 13.5)

6.8 (5.8, 8.0)

6.2 (5.1, 7.3)

-

-

-

-

Fasting insulin (pmol/l) c

78.8 (47.9, 99.9)

81.0 (53.8, 129.4)

69.3 (47.7, 99.9)

57.6 (40.5, 81.0)

-

-

-

-

HbA1c (mmol/mol) d

50.0 (43.0, 66.0)

45.0 (40.0, 52.0)

38.0 (34.0, 40.0)

38.0 (36.0, 40.0)

48.6 (44.0, 55.2)

47.5 (42.3, 51.7)

37.7 (33.7, 39.4)

36.6 (34.4, 39.0)

HbA1c (%) d

6.7 (6.1, 8.2)

6.3 (5.8, 6.9)

5.6 (5.3, 5.8)

5.6 (5.4, 5.8)

6.6 (6.2, 7.2)

6.5 (6.0, 6.9)

5.6 (5.2, 5.8)

5.5 (5.3, 5.7)

Fasting status (yes, %)

23 (51.1)

113 (61.7)

98 (96.1)

1083 (93.2)

0 (0)

8 (5.5)

4 (7.8)

44 (6.5)

Education (years)

10 (8, 11)

10 (8, 11)

10 (10, 12)

10 (10, 12)

10 (9, 10)

10 (10, 11)

10 (10, 12)

10 (10, 12)

Physical activity (active, %) e

5 (11.1)

60 (33.0)

36 (35.6)

524 (45.1)

7 (36.8)

80 (54.8)

21 (41.2)

398 (59.2)

Current smoker (%)

10 (22.2)

24 (13.1)

17 (16.7)

157 (13.5)

1 (5.3)

6 (4.1)

4 (7.8)

27 (4.0)

Alcohol consumption (%) e

        

None

16 (35.6)

64 (35.2)

26 (25.7)

306 (26.4)

11 (57.9)

61 (41.8)

19 (37.3)

223 (33.2)

Moderate

20 (44.4)

86 (47.2)

55 (54.5)

611 (52.6)

8 (42.1)

69 (47.3)

19 (37.3)

345 (51.3)

High

9 (20.0)

32 (17.6)

20 (19.8)

244 (21.0)

0 (0)

16 (10.9)

13 (25.4)

104 (15.5)

Medication use (%)

        

Antihypertensive drugs

20 (44.4)

94 (51.4)

49 (48.0)

361 (31.1)

18 (94.7)

122 (83.6)

38 (74.5)

431 (64.1)

Statins

4 (8.9)

27 (14.8)

9 (8.8)

91 (7.8)

8 (42.1)

52 (35.6)

14 (27.5)

149 (22.2)

Lipid-lowering drugs

6 (13.3)

32 (17.5)

11 (10.8)

107 (9.2)

8 (42.1)

56 (38.4)

15 (29.4)

153 (22.8)

  1. Note: Data are presented as median (25th, 75th percentile) for continuous variables and n (%) for categorical variables
  2. Abbreviations: BMI: body mass index; CHD: coronary heart disease; HbA1c: haemoglobin A1c; HDL: high-density lipoprotein; T2D: type 2 diabetes
  3. a Data were calculated in 129 participants with T2D (20 CHD cases vs. 109 noncases) and 1173 participants without T2D (98 CHD cases vs. 1075 noncases) at KORA S4.
  4. b Data were calculated in 121 participants with T2D (18 CHD cases vs. 103 noncases) and 1141 participants without T2D (96 CHD cases vs. 1045 noncases) at KORA S4.
  5. c Data were calculated in 134 participants with T2D (22 CHD cases vs. 112 noncases) and 1141 participants without T2D (95 CHD cases vs. 1046 noncases) at KORA S4.
  6. d Data were calculated in 1262 participants without T2D (102 CHD cases vs. 1160 noncases) at KORA S4.
  7. e Data were calculated in 227 participants with T2D (45 CHD cases vs. 182 noncases) and 1261 participants without T2D (101 CHD cases vs. 1161 noncases) at KORA S4